https://classic.clinicaltrials.gov/ct2/show/NCT05643729
Clinical Trials
Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients
https://clinicaltrials.gov/ct2/show/NCT04072887?type=Intr&cond=COPD&sfpd_d=14&sel_rss=new14 Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients Condition : Pulmonary Disease, Chronic Obstructive Interventions : Drug: QBW251; Drug: Placebo Sponsor : Novartis Pharmaceuticals Not yet recruiting NCT04072887 Wed, 28 Aug 2019 12:00:00 EDT
Fiber Metabolism in Chronic Obstructive Pulmonary Disease
https://clinicaltrials.gov/ct2/show/NCT04459156?type=Intr https://clinicaltrials.gov/ct2/show/NCT04459156?type=Intr&cond=COPD&sfpd_d=14&sel_rss=new14 Fiber Metabolism in Chronic Obstructive Pulmonary Disease Condition : Chronic Obstructive Pulmonary Disease Interventions : Dietary Supplement: Fiber Inulin; Dietary Supplement: Placebo Maltodextrin Sponsor : Texas A&M University Recruiting NCT04459156 Tue, 07 Jul 2020 12:00:00 EDT
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab (SAR231893) in Patients With Moderate to Severe COPD With Type 2 Inflammation
https://clinicaltrials.gov/ct2/show/NCT04456673?type=Intr https://clinicaltrials.gov/ct2/show/NCT04456673?type=Intr&cond=COPD&sfpd_d=14&sel_rss=new14 Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation Condition : Chronic Obstructive Pulmonary Disease Interventions : Drug: Dupilumab SAR231893; Drug: Inhaled Corticosteroid; Drug: Inhaled Long-Acting Beta Agonist; Drug: Inhaled Long-Acting Muscarinic Antagonist; Drug: Placebo Sponsors : Sanofi; Regeneron Pharmaceuticals Recruiting NCT04456673 Thu, 02 Jul 2020 12:00:00 EDT
A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease
https://clinicaltrials.gov/ct2/show/NCT04091360?type=Intr&cond=COPD&sfpd_d=14&sel_rss=new14 A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease Condition : COPD Interventions : Drug: Ensifentrine 100mcg; Drug: Ensifentrine 300mcg; Drug: Ensifentrine 1000mcg; Drug: Ensifentrine 3000mcg; Drug: Ensifentrine 6000mcg; Drug: Placebos Sponsors : Verona Pharma plc; Iqvia Pty Ltd Recruiting NCT04091360 Mon, 16 Sep 2019 12:00:00 EDT
The Safety and Feasibility of UMC119-06 Cell Therapy (Mesenchymal Stem Cells) in Subjects With Chronic Obstructive Pulmonary Disease
https://clinicaltrials.gov/ct2/show/NCT04206007?type=Intr&cond=COPD&sfpd_d=14&sel_rss=new14 Mesenchymal Stem Cells for The Treatment of Chronic Obstructive Pulmonary Disease The Safety and Feasibility of UMC119-06 Cell Therapy in Subjects With Chronic Obstructive Pulmonary Disease Condition : Chronic Obstructive Pulmonary Disease Moderate Intervention : Biological: UMC119-06 Sponsor : Meridigen Biotech Co., Ltd. Not yet recruiting NCT04206007 Fri, 20 Dec 2019 12:00:00 EST
Mesenchymal Stem Cells in the Treatment of Subjects With Advance Chronic Obstructive Pulmonary Disease (COPD)
https://clinicaltrials.gov/ct2/show/NCT04047810?type=Intr&cond=COPD&sfpd_d=14&sel_rss=new14 Mesenchymal Stem Cells in the Treatment of Subjects With Advance Chronic Obstructive Pulmonary Disease (COPD) Condition : Chronic Obstructive Pulmonary Disease Intervention : Biological: Mesenchymal Stem Cells Sponsor : Mayo Clinic Not yet recruiting NCT04047810 Wed, 07 Aug 2019 12:00:00 EDT
The Use of Benralizumab, an Interleukin-5 Receptor-α Monoclonal Antibody as Treatment of Acute Exacerbations of Airways Disease
https://clinicaltrials.gov/ct2/show/NCT04098718?type=Intr&cond=COPD&sfpd_d=14&sel_rss=new14 Acute Exacerbations Treated With BenRAlizumab (The ABRA Study) Conditions : Asthma; COPD Interventions : Drug: Benralizumab; Drug: Prednisolone Sponsor : University of Oxford Not yet recruiting NCT04098718 Mon, 23 Sep 2019 12:00:00 EDT
Study to evaluate the impact of inhaled PT003 in moderate to severe COPD patients
https://clinicaltrials.gov/ct2/show/NCT04087590?type=Intr&cond=COPD&sfpd_d=14&sel_rss=new14 Impact of Inhaled PT003 on Complexity and Variability of Tidal Breathing and Oscillatory Mechanics in Stable COPD Patient Condition : Copd Intervention : Drug: Formoterol-glycopyrronium co suspension (PT003) Sponsors : University Hospital, Lille; AstraZeneca Not yet recruiting NCT04087590 Thu, 12 Sep 2019 12:00:00 EDT
Investigate the Safety, Tolerability and Pharmacokinetics of CHF6523 in Healthy and in COPD Subjects
https://clinicaltrials.gov/ct2/show/NCT04032535 Investigate the Safety, Tolerability and Pharmacokinetics of CHF6523 in Healthy and in COPD Subjects (CHF6523)
Photobiomodulation in Individuals With Chronic Obstructive Pulmonary Disease
https://clinicaltrials.gov/ct2/show/NCT04010084?type=Intr&cond=COPD&sfpd_d=14&sel_rss=new14 Photobiomodulation in Individuals With Chronic Obstructive Pulmonary Disease Condition : Chronic Obstructive Pulmonary Disease Interventions : Radiation: Low level laser therapy; Procedure: Placebo group Sponsor : University of Nove de Julho Not yet recruiting NCT04010084 Mon, 08 Jul 2019 12:00:00 EDT Effectiveness of Photobiomodulation in Individuals With Chronic Obstructive Pulmonary Disease – Randomized Clinical Trial
The Effectiveness of Bottle-PEP in Chronic Obstructive Pulmonary Disease
https://clinicaltrials.gov/ct2/show/NCT03900195?type=Intr&cond=COPD&sfpd_d=14&sel_rss=new14 The Effectiveness of Bottle-PEP in Chronic Obstructive Pulmonary Disease Condition : Chronic Obstructive Pulmonary Disease Intervention : Other: BottlePEP Sponsor : Marmara University Recruiting NCT03900195 Tue, 02 Apr 2019 12:00:00 EDT Phase N/A
The Effect of FP-025, a MMP-12 Inhibitor, on Airway Responses and Airway Inflammation
https://clinicaltrials.gov/ct2/show/NCT03858686?type=Intr&cond=COPD&phase=01234&lupd_s=02%2F15%2F2019&lupd_d=14&sort=nwst The Effect of FP-025, a MMP-12 Inhibitor, on Allergen-induced Airway Responses and Airway Inflammation in Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma Condition : Asthma, COPD Interventions : Drug: FP-025 capsules; Drug: Placebo FP-025 capsules Sponsor : Foresee Pharmaceuticals Co., Ltd. Recruiting NCT03858686 Fri, 01 Mar 2019 12:00:00 EST
The Effects of RPL554 in Addition to Tiotropium in COPD Patients [Completed]
https://clinicaltrials.gov/ct2/show/NCT03028142?type=Intr https://clinicaltrials.gov/ct2/show/NCT03028142?type=Intr&cond=COPD&phase=01234&lupd_s=01%2F09%2F2019&lupd_d=14&sort=nwst The Effects of RPL554 in Addition to Tiotropium in COPD Patients Condition : Chronic Obstructive Pulmonary Disease Moderate Interventions : Drug: 1.5 mg RPL554 plus tiotropium; Drug: 6 mg RPL554 plus tiotropium; Drug: Placebo plus tiotropium Sponsor : Verona Pharma plc Completed NCT03028142 Mon, 23 Jan 2017 12:00:00 EST
Arbidol for COPD Exacerbations
https://clinicaltrials.gov/ct2/show/NCT03851991?type=Intr&cond=COPD&phase=01234&lupd_s=02%2F08%2F2019&lupd_d=14&sort=nwst Arbidol for COPD Exacerbations Condition : COPD Patients Interventions : Drug: Arbidol; Drug: Placebos Sponsor : Shengjing Hospital Not yet recruiting NCT03851991 Fri, 22 Feb 2019 12:00:00 EST Last Update Posted: 26 Feb 2019
A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia
https://clinicaltrials.gov/ct2/show/NCT03810183?type=Intr&cond=COPD&phase=01234&lupd_s=01%2F04%2F2019&lupd_d=14&sort=nwst A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia Condition : COPD Interventions : Drug: QAW039; Drug: Placebo Sponsor : Novartis Pharmaceuticals Not yet recruiting NCT03810183 Fri, 18 Jan 2019 12:00:00 EST
Safety and Tolerability of MEDI3506 in Healthy Subjects, in Subjects With COPD and Healthy Japanese Subjects
https://clinicaltrials.gov/ct2/show/NCT03096795 Safety and Tolerability of MEDI3506 in Healthy Subjects, in Subjects With COPD and Healthy Japanese SubjectsClinicalTrials.gov Identifier: NCT03096795 Recruitment Status : Recruiting First Posted : March 30, 2017 Last Update Posted : January 8, 2019 See Contacts and Locations Sponsor: MedImmune LLC Information provided by (Responsible Party): MedImmune LLC Study Details Tabular ViewNo Results […]
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
https://clinicaltrials.gov/ct2/show/NCT02459080?type=Intr&cond=COPD&phase=01234&lupd_s=12%2F17%2F2018&lupd_d=14&sort=nwst Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD) Condition : Chronic Obstructive Pulmonary Disease (COPD) Interventions : Drug: TD-4208; Drug: Placebo Sponsor : Theravance Biopharma Completed NCT02459080 Mon, 01 Jun 2015 12:00:00 EDT
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
https://clinicaltrials.gov/ct2/show/NCT02518139?type=Intr&cond=COPD&phase=01234&lupd_s=12%2F17%2F2018&lupd_d=14&sort=nwst A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD) Condition : Chronic Obstructive Pulmonary Disease (COPD) Interventions : Drug: TD-4208; Drug: Tiotropium Sponsor : Theravance Biopharma Completed NCT02518139 Fri, 07 Aug 2015 12:00:00 EDT
A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza
https://clinicaltrials.gov/ct2/show/NCT03570359?type=Intr&cond=COPD&phase=01234&lupd_s=12%2F17%2F2018&lupd_d=14&sort=nwst A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza Condition : Chronic Obstructive Pulmonary Disease (COPD) Interventions : Drug: Interferon Beta-1A; Other: Placebo Sponsor : Synairgen Research Ltd. Recruiting NCT03570359 Wed, 27 Jun 2018 12:00:00 EDT
Effect of Vitamin D3 on Lung Function and Exercise Tolerance in COPD Patients
https://clinicaltrials.gov/ct2/show/NCT03781895?type=Intr&cond=COPD&phase=01234&sfpd_d=14&sort=nwst&sel_rss=new14 Effect of Vitamin D3 on Lung Function and Exercise Tolerance in COPD Patients Condition : Stable COPD Patients Intervention : Drug: Cholecalciferol Sponsor : Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh Completed NCT03781895 Thu, 20 Dec 2018 12:00:00 EST >>> updated dec 25, completed
Alvelestat (MPH996) for the Treatment of ALpha-1 ANTitrypsin Deficiency
https://clinicaltrials.gov/ct2/show/NCT03679598?type=Intr&cond=COPD&phase=01234&lupd_s=12%2F13%2F2018&lupd_d=14&sort=nwst Alvelestat (MPH996) for the Treatment of ALpha-1 ANTitrypsin Deficiency Conditions : Alpha-1 Antitrypsin Deficiency (AATD); Pi*ZZ, Pi*SZ, or Pi*Null Phenotype; Emphysema or COPD Interventions : Drug: Alvelestat (MPH996); Other: Placebo Sponsors : University of Alabama at Birmingham; National Institutes of Health (NIH); Mereo BioPharma Not yet recruiting NCT03679598 Thu, 20 Sep 2018 12:00:00 EDT >>> updated dec 18, 2018
A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases
https://clinicaltrials.gov/ct2/show/NCT03645434?type=Intr&cond=COPD&phase=01234&lupd_s=10%2F25%2F2018&lupd_d=14&sort=nwst A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases. Condition : Chronic Obstructive Pulmonary Disease Interventions : Drug: AZD8871; Drug: Anoro® Ellipta® Sponsors : AstraZeneca; Parexel Recruiting NCT03645434 Fri, 24 Aug 2018 12:00:00 EDT
A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo
https://clinicaltrials.gov/ct2/show/NCT03636347?type=Intr&cond=COPD&phase=01234&lupd_s=11%2F01%2F2018&lupd_d=14&sort=nwst A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo. Conditions : Alpha 1-Antitrypsin Deficiency; Emphysema; COPD Interventions : Drug: Placebo Oral Tablet; Drug: Alvelestat oral tablet – dose 1; Drug: Alvelestat oral tablet – dose 2 Sponsors : Mereo BioPharma; Syneos Health Recruiting NCT03636347 Fri, 17 Aug 2018 12:00:00 EDT
Prevention of Acute Exacerbation in Subjects With COPD by Bacterial Decolonization in Lower Respiratory Tract
https://clinicaltrials.gov/ct2/show/NCT03449459?type=Intr&cond=COPD&phase=01234&lupd_s=11%2F01%2F2018&lupd_d=14&sort=nwst Prevention of Acute Exacerbation in Subjects With COPD by Bacterial Decolonization in Lower Respiratory Tract Condition : Chronic Obstructive Pulmonary Disease (COPD) Interventions : Dietary Supplement: oral probiotics; Drug: aerosol inhaled amikacin; Biological: combined vaccination Sponsors : Shanghai Zhongshan Hospital; The First Affiliated Hospital of Guangzhou Medical University; Ruijin Hospital Not yet recruiting NCT03449459 Wed, 28 Feb 2018 12:00:00 EST
Home Non Invasive Ventilation (NIV) Treatment for COPD-patients After a NIV-treated Exacerbation
https://clinicaltrials.gov/ct2/show/NCT01513655?type=Intr&cond=COPD&phase=01234&lupd_s=11%2F02%2F2018&lupd_d=14&sort=nwst Home Non Invasive Ventilation (NIV) Treatment for COPD-patients After a NIV-treated Exacerbation Conditions : Chronic Obstructive Pulmonary Disease; Acute Exacerbation of Chronic Obstructive Airways Disease; Chronic Hypercapnic Respiratory Failure Intervention : Device: LTNIV Sponsors : University Hospital, Gentofte, Copenhagen; Philips Respironics Recruiting NCT01513655 Fri, 20 Jan 2012 12:00:00 EST UPDATE: now recruiting
Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells In Chronic Lung Disorders
https://clinicaltrials.gov/ct2/show/NCT02946658?type=Intr&cond=COPD&phase=01234&lupd_s=10%2F25%2F2018&lupd_d=14&sort=nwst Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells In Chronic Lung Disorders Condition : Lung Disease Interventions : Procedure: lipoaspiration; Procedure: ADcSVF; Procedure: Normal Saline IV Sponsors : Healeon Medical Inc; Terry, Glenn C., M.D. Recruiting NCT02946658 Thu, 27 Oct 2016 12:00:00 EDT
A Study to Assess the Efficacy of a 5-day, 10- mg PBF-680 Oral Administration on Late Asthmatic Responses (LAR) in Mild to Moderate Asthmatic Patients
https://clinicaltrials.gov/ct2/show/NCT02635945?type=Intr&cond=COPD&phase=01234&lupd_s=10%2F23%2F2018&lupd_d=14&sort=nwst A Study to Assess the Efficacy of a 5-day, 10- mg PBF-680 Oral Administration on Late Asthmatic Responses (LAR) in Mild to Moderate Asthmatic Patients. Condition : Asthma Interventions : Drug: PBF-680; Drug: Placebo Sponsors : Palobiofarma SL; Fundació Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau; […]
Autologous Transplantation of Bronchial Basal Cells for Treatment of COPD
https://clinicaltrials.gov/ct2/show/NCT03655795?type=Intr&cond=COPD&phase=01234&lupd_s=10%2F23%2F2018&lupd_d=14&sort=nwst Autologous Transplantation of Bronchial Basal Cells for Treatment of COPD Condition : COPD Intervention : Biological: Bronchial basal cells Sponsors : Ruijin Hospital; Regend Therapeutics Not yet recruiting NCT03655795 Fri, 31 Aug 2018 12:00:00 EDT
Anti-ST2 (MSTT1041A) in COPD (COPD-ST2OP)
https://clinicaltrials.gov/ct2/show/NCT03615040?type=Intr&cond=COPD&phase=01234&lupd_s=10%2F19%2F2018&lupd_d=14&sort=nwst Anti-ST2 (MSTT1041A) in COPD (COPD-ST2OP) Condition : COPD Exacerbation Interventions : Drug: MSTT1041A; Drug: Placebo Sponsors : University of Leicester; Biomedical Research Centre- Respiratory (Glenfield Hospital, Leicester UK); Leicester Clinical Trials Unit; Genentech, Inc. Recruiting NCT03615040 Fri, 03 Aug 2018 12:00:00 EDT
A Pilot Study of the Use of Metformin to Reduce Airway Glucose in COPD
https://clinicaltrials.gov/ct2/show/NCT03651895?type=Intr&cond=COPD&phase=04&sfpd_d=14&sort=nwst&sel_rss=new14 Chronic obstructive pulmonary disease (COPD) is the 4th leading cause of death worldwide and affects 1.2 million people in the UK, costing the NHS >£800 million annually. COPD patients are more susceptible to bacterial infections and both chronic and acute infections are common. COPD patients with chronic lung bacterial infection have worse quality of […]